Infantile Polycystic Kidney Disease Medical Services in China

Infantile Polycystic Kidney Disease (IPKD), now more accurately termed Autosomal Recessive Polycystic Kidney Disease (ARPKD), is a rare, life-threatening genetic disorder characterized by bilateral renal cystic dilation of the collecting ducts and congenital hepatic fibrosis. It results from biallelic pathogenic variants in the PKHD1 gene on chromosome 6p12.2, which encodes fibrocystin/polyductin — a ciliary protein critical for normal tubular morphogenesis and bile duct development. Dysfunctional fibrocystin disrupts planar cell polarity, cilia-mediated signaling (e.g., cAMP, Wnt, and Hedgehog pathways), and epithelial integrity, leading to progressive cyst formation in kidneys and periportal fibrosis in the liver. Unlike autosomal dominant PKD, ARPKD manifests prenatally or in early infancy, with severity varying widely: severe cases present with oligohydramnios, Potter sequence, pulmonary hypoplasia, and neonatal respiratory failure; milder forms may present later with hypertension, renal insufficiency, or portal hypertension due to liver involvement. The estimated incidence is 1 in 20,000 to 1 in 40,000 live births, with carrier frequency ~1:70 in the general population. Consanguinity significantly increases risk, and no sex predilection exists. Diagnosis relies on prenatal ultrasound (enlarged, echogenic kidneys ± oligohydramnios), postnatal imaging (renal ultrasound showing symmetric enlargement and increased echogenicity; MRI for hepatic fibrosis assessment), and confirmatory genetic testing. Complications include chronic kidney disease (CKD) progressing to end-stage renal disease (ESRD) in ~30–50% by age 10–15 years, systemic hypertension (often refractory), urinary tract infections, growth failure, and complications of portal hypertension (variceal bleeding, hypersplenism). Quality of life is profoundly impacted: infants face intensive neonatal care and recurrent hospitalizations; children experience developmental delays, school absenteeism, dietary restrictions, and psychosocial stress related to chronic illness, dialysis dependence, or transplant candidacy. Families endure emotional burden, financial strain, and caregiving demands. Long-term management requires multidisciplinary coordination among pediatric nephrology, hepatology, nutrition, genetics, and palliative care. While no disease-modifying therapy yet exists, supportive care—aggressive blood pressure control, electrolyte management, nutritional support, infection prophylaxis, and timely renal replacement therapy—is essential to optimize survival and neurodevelopmental outcomes. Emerging research focuses on CFTR modulation, cAMP inhibition, and antifibrotic agents, but clinical translation remains investigational.

Infantile Polycystic Kidney Disease (IPKD), now more accurately classified under the broader entity of Autosomal Recessive Polycystic Kidney Disease (ARPKD), is a rare, genetically inherited disorder caused by mutations in the PKHD1 gene. It manifests prenatally or in early infancy with bilateral, symmetrically enlarged kidneys due to fusiform dilatation of collecting ducts, accompanied by congenital hepatic fibrosis and variable pulmonary hypoplasia. Prognosis is highly heterogeneous: severe perinatal forms may present with Potter sequence and respiratory failure, while milder cases may survive into childhood or adulthood with progressive renal and hepatic complications. Management requires a multidisciplinary approach coordinated by pediatric nephrology, hepatology, pulmonology, nutrition, and genetics. Treatment is primarily supportive and organ-system–directed, as no disease-modifying pharmacotherapy is currently FDA- or EMA-approved for ARPKD.

Conservative management forms the cornerstone of care, especially in neonates and infants. Respiratory support is critical in the immediate postnatal period; up to 30% of severely affected neonates require mechanical ventilation due to pulmonary hypoplasia and impaired gas exchange. Continuous positive airway pressure (CPAP) or high-frequency oscillatory ventilation may be employed judiciously to avoid barotrauma. Fluid and electrolyte balance must be meticulously monitored: infants often exhibit polyuria secondary to impaired urinary concentrating ability, predisposing them to dehydration and hypernatremia. Oral or intravenous sodium supplementation may be necessary, particularly during intercurrent illness. Nutritional support is paramount—many infants suffer from failure to thrive due to increased metabolic demand, feeding intolerance, or gastroesophageal reflux. A high-calorie, low-sodium, age-appropriate formula—often supplemented with medium-chain triglyceride (MCT) oil for enhanced caloric density—is recommended. Gastrostomy tube placement may be indicated for persistent poor oral intake or aspiration risk. Regular surveillance includes serial renal ultrasound (to assess cyst burden, parenchymal echogenicity, and cortical thinning), Doppler assessment of renal artery flow, and measurement of glomerular filtration rate (GFR) via serum cystatin C–based equations (e.g., Schwartz-Lyon). Hepatic involvement necessitates periodic liver enzyme panels, abdominal ultrasound with elastography, and screening for portal hypertension (e.g., platelet count, splenomegaly, esophageal varices via endoscopy if clinically indicated).

Pharmacologic interventions remain largely symptomatic. Antihypertensive therapy is initiated promptly upon diagnosis of hypertension—present in >60% of older infants and children—with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) preferred due to their renoprotective effects and antiproteinuric properties. Diuretics (e.g., furosemide) are used cautiously to manage volume overload but avoided in dehydrated states. Growth hormone therapy may be considered in children with documented growth failure refractory to nutritional optimization, though evidence specific to ARPKD remains limited. Antibiotic prophylaxis is not routinely recommended, but prompt treatment of urinary tract infections (UTIs) is essential given the risk of pyelonephritis-induced renal scarring. Chronic kidney disease (CKD)-related complications—including anemia (managed with erythropoiesis-stimulating agents and iron supplementation), metabolic acidosis (corrected with oral sodium bicarbonate), and mineral bone disorder (treated with phosphate binders and active vitamin D analogs)—are addressed per KDIGO guidelines.

Surgical intervention is reserved for specific complications. Nephrectomy is rarely performed except in cases of massive, symptomatic renal enlargement causing respiratory compromise, intractable pain, recurrent infection, or severe hypertension unresponsive to medical therapy. Laparoscopic or robotic-assisted partial nephrectomy may be considered in select older children to preserve residual function, though data on long-term benefit are sparse. Portosystemic shunting (e.g., mesocaval shunt) or transjugular intrahepatic portosystemic shunt (TIPS) may be palliative for life-threatening variceal bleeding, though surgical shunts carry higher morbidity in young children. Liver transplantation is indicated for decompensated cirrhosis, recurrent variceal hemorrhage, or intractable ascites; combined liver-kidney transplantation is increasingly performed in patients with end-stage renal disease (ESRD) and advanced hepatic fibrosis, offering superior long-term survival compared to isolated kidney transplant due to reduced risk of native kidney recurrence and perioperative complications. Dialysis—peritoneal dialysis (PD) is first-line in infants due to hemodynamic stability and technical feasibility—bridges patients to transplantation. Hemodialysis is typically deferred until age 2–3 years unless PD fails.

China offers distinct advantages in the comprehensive management of ARPKD. First, the national newborn screening program—though not yet including ARPKD universally—has expanded prenatal ultrasound access, enabling earlier detection and referral to tertiary centers such as Peking University First Hospital and Shanghai Children’s Medical Center, both designated National Clinical Research Centers for Pediatric Nephrology. Second, China’s robust organ transplantation infrastructure, supported by the China Organ Transplant Response System (COTRS), has significantly shortened wait times for pediatric liver and kidney grafts; median wait time for pediatric liver transplant is now <6 months versus >12 months in many Western countries. Third, integrated traditional Chinese medicine (TCM) adjuncts—such as modified Liuwei Dihuang Wan or Huangqi decoctions—are rigorously studied in randomized controlled trials at institutions like Guangzhou University of Chinese Medicine and demonstrate potential benefits in reducing proteinuria and slowing eGFR decline, though mechanistic validation is ongoing. Fourth, telemedicine-enabled longitudinal follow-up through platforms like WeDoctor facilitates seamless coordination between provincial hospitals and national centers, improving adherence to surveillance protocols and early complication detection.

Recovery and long-term prognosis hinge on proactive, family-centered education and lifestyle adaptation. Parents should receive structured counseling on recognizing signs of dehydration (e.g., decreased wet diapers, sunken fontanelle), UTI (fever, irritability, foul-smelling urine), or variceal bleed (hematemesis, melena). Vaccination schedules must be strictly adhered to, with emphasis on pneumococcal, hepatitis B, and annual influenza vaccines; live vaccines are contraindicated in immunosuppressed transplant recipients. School reintegration planning should include individualized health plans addressing fatigue, medication timing, and bathroom access. Psychological support—via child life specialists and clinical psychologists—is integral, as children with ARPKD face elevated risks of anxiety, depression, and social isolation. Finally, genetic counseling is mandatory: recurrence risk is 25% for future pregnancies, and prenatal testing (chorionic villus sampling or amniocentesis with PKHD1 sequencing) or preimplantation genetic diagnosis (PGD) should be offered. With optimized conservative care, timely transplantation, and integrated psychosocial support, over 85% of children with non-lethal neonatal ARPKD now survive beyond age 5, and many achieve near-normal quality of life into adulthood.